Table 6. In vitro inhibitory activities of 6b, 7b, 8b, 12a–c, and 13b against CDK6, VEGFR-2 and xanthine oxidase enzymes compared with palbociclib, sorafenib and allopurinol reference compounds, respectively.
| Entry | pIC50 CDK6 ± SD | pIC50 VEGFR-2 ± SD | pIC50 XO ± SD |
|---|---|---|---|
| 6a | 6.22 ± 0.023 | 6.51 ± 0.012 | 4.36 ± 0.55 |
| 7b | 5.82 ± 0.059 | 6.29 ± 0.02 | 4.18 ± 0.82 |
| 8b | 7.17 ± 0.003 | 7.15 ± 0.003 | 4.66 ± 0.33 |
| 12a | 6.81 ± 0.006 | 7.27 ± 0.002 | 4.94 ± 0.16 |
| 12b | 6.91 ± 0.048 | 6.92 ± 0.006 | 4.51 ± 0.62 |
| 12c | 6.93 ± 0.005 | 6.84 ± 0.009 | 4.83 ± 0.23 |
| 13b | 6.09 ± 0.032 | 6.49 ± 0.012 | 4.41 ± 0.49 |
| Palbociclib | 6.79 ± 0.006 | — | — |
| Sorafenib | — | 7.25 ± 0.002 | — |
| Allopurinol | — | — | 4.57 ± 0.13 |